Donanemab-azbt (Kisunla) demonstrates distinct advantages and trade-offs compared to other Alzheimer's treatments, particularly monoclonal antibody therapies like lecanemab and aducanumab. Here's a structured comparison:
Mechanism of Action
Donanemab: Targets mature, aggregated amyloid-beta plaques (N-terminal pyroglutamate Aβ)[2][5].
Lecanemab: Binds soluble Aβ protofibrils earlier in plaque formation[2][6].
Aducanumab: Recognizes both fibrillar and soluble Aβ aggregates[4].
Cognitive & Functional Efficacy
Treatment | Cognitive Decline Reduction | Key Trial Findings |
Donanemab | 35% (low/medium tau group)[1][5] | 39% lower disease progression risk; 47% halted progression at 1 year[5] |
Lecanemab | 27% (ADAS-Cog)[4] | Slower decline in daily living scores vs donanemab[3] |
Aducanumab | 22% (ADAS-Cog)[4] | Less effective than donanemab/lecanemab in network meta-analyses[4][6] |
Donanemab showed 3× greater effect size than lecanemab/aducanumab on the Clinical Dementia Rating scale (CDR-SB) in head-to-head analyses[6].
Amyloid Clearance
Speed: Donanemab clears plaques faster (84% reduction at 18 months vs lecanemab’s 59% at 18 months)[5][6].
Dosing Protocol:
Donanemab: Monthly infusions with potential treatment cessation upon plaque clearance[5]
Lecanemab: Biweekly indefinite infusions[2]
Safety Profile
Adverse Event | Donanemab | Lecanemab | Aducanumab |
ARIA-Edema (ARIA-E) | 24%[1] | 12.6%[3] | 35%[4] |
Microhemorrhages | 25%[1] | 17%[3] | 19%[4] |
Treatment-related deaths | 0.3%[1] | 0.7%[3] | 0.4%[4] |
Donanemab has higher ARIA risk than lecanemab but lower mortality risk[1][3]. All three antibodies show worse tolerability than placebo[4].
Practical Considerations
Patient Selection:
Donanemab works best in low/medium tau populations (no significant effect in high tau)[5]
Requires APOE ε4 testing due to ARIA risk stratification[1]
Monitoring Burden:
Donanemab: Frequent MRIs (5 scans in first 7 months)[1]
Lecanemab: Less intensive monitoring but lifelong dosing[2]
Cost/Workflow:
Donanemab’s potential finite treatment duration (6-18 months) may reduce long-term costs[5]
Both require specialized infusion centers[2][5]
Emerging Comparisons
Lithium: Outperformed donanemab on MMSE in meta-analyses but lacks large-scale AD validation[4]
Combination Therapies: Research ongoing with tau-targeting drugs to address donanemab’s limited efficacy in high-tau patients[5]
Donanemab offers a time-limited treatment option with strong cognitive benefits for early AD patients, but requires careful risk-benefit analysis due to monitoring demands and ARIA risks. Lecanemab may be preferable for patients needing lower ARIA risk tolerance, while aducanumab lags in efficacy comparisons[3][4][6].
Citations:
[1] https://www.nia.nih.gov/news/nia-statement-donanemab-results-more-alzheimers-research-progress
[2] https://mylocalinfusion.com/donanemab-vs-lecanemab/
[4] https://pubmed.ncbi.nlm.nih.gov/38253184/
[6] https://www.medrxiv.org/content/10.1101/2024.03.31.24305134v1.full-text
[7] https://pmc.ncbi.nlm.nih.gov/articles/PMC11097689/
[8] https://www.drugs.com/medical-answers/how-decide-between-leqembi-kisunla-3578170/
[9] https://pmc.ncbi.nlm.nih.gov/articles/PMC11098549/
[10] https://www.explorationpub.com/Journals/en/Article/100648
Share this post